Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Autologous-adipose-derived-mesenchymal-stem-cell-therapy-Celltex-Therapeutics (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Celltex Therapeutics
- 20 Nov 2019 Planned primary completion date changed from 15 Dec 2022 to 15 Dec 2021.
- 20 Nov 2019 Planned initiation date changed from 15 Dec 2019 to 1 Feb 2020.
- 18 Nov 2019 Status changed from planning to not yet recruiting.